. Redfors (1972) defined an optimal serum concentration for longterm control of atrial fibrillation, and sustained inotopic effect has been shown at a similar concentration in patients in sinus rhythm (Dobbs et al., 1977a) . Smith and Haber (1970) receiving maintenance digoxin agreed to take part in the study. The mean age (± 1 SD) was 59 + 12 years, mean weight 62 ± 13 kg, and mean creatinine clearance 60 ± 23 ml/min.
Although, ideally, the dose of digoxin should be chosen by titration against response, this may be difficult. Rapid ventricular rates in atrial fibrillation do not always respond to digoxin, and evaluation of the inotropic effect may be confounded by re- sponse to other interventions. Moreover the less serious manifestations of toxicity, such as nausea, anorexia, and fatigue, do not serve as a reliable warning of cardiotoxicity.
Measurement of the serum digoxin concentration has proved of use in choosing the dose for individual patients (Sheiner, 1974) . Redfors (1972) defined an optimal serum concentration for longterm control of atrial fibrillation, and sustained inotopic effect has been shown at a similar concentration in patients in sinus rhythm (Dobbs et al., 1977a) . Smith and Haber (1970) defined a ceiling concentration below which the risk of cardiotoxicity was small. However, in practice, the value of the assay is limited by its restricted availability and by delays in receiving results. We describe a simple method for prescribing digoxin based on readily available information.
Patients and methods
One hundred and twenty-nine patients (110 outpatients and 19 inpatients; 67 men and 62 women)
Received for publication 23 August 1977 receiving maintenance digoxin agreed to take part in the study. The mean age (± 1 SD) was 59 + 12 years, mean weight 62 ± 13 kg, and mean creatinine clearance 60 ± 23 ml/min.
At the first interview the previous supply of digoxin tablets was collected and an equivalent daily dose of 'Lanoxin' dispensed. Having allowed at least three weeks for 'steady state' (Wagner et al., 1965) conditions to be attained, venous blood samples for digoxin assay were taken on an average of four occasions per patient. Blood was sampled immediately before a daily dose (10 am). The mean steady state serum concentration, C nmol/l, was estimated from the predose concentration, Co nmol/l, using the equation C = 0 37 + 1-08 Co (Dobbs et al., 1976c) . In 14 patients this equation was not applicable because of poor renal function, so the concentration 6 hours after the daily dose was taken as a direct measure of the mean steady state con-P. W. Nicholson, Sylvia M. Dobbs, A. P. Jt. McGill, Elaine M. Rodgers, and E. Slater agents Ltd.). The between assay coefficient of variation of a serum sample assayed in duplicate was 10 per cent at a concentration of 1-3 nmol/l and of 2-6 nmol/l.
PATIENT CHARACTERISTICS
The following were recorded for each patient: out/inpatient status, sex, age, weight, height, biacromial and bitrochanteric diameters, mobility (whether chronically house-or chair-bound or not), and previous history with respect to renal disease. The patients were graded according to their symptoms and signs of cardiac disease (Dobbs et al., 1977a) and questioned about other drugs taken with special reference to diuretics, antacids (Binnion and McDermott, 1972) , and purgatives (Manninien et al., 1973 (Chamberlain et al., 1970; Smith and Haber, 1970) (1 28-2-56 nmol/l), and close to Redfors' (1972) optimum, was selected. The dose required by each patient to achieve this target, 'the dose requirement', was calculated assuming proportionality between the amount of digoxin given daily to an individual and the mean concentration achieved (Wagner et al., 1965; Dobbs et al., 1976b) .
Multiple linear regression analysis (Nie et al., 1975) about the mean (total sum of squares), representing the original variation in y, may be partitioned into a regression sum of squares, the variation explained by the equation, and the residual sum of squares the unexplained variation. Coefficients, bo, b1, b2 . . . bk, are chosen to give a minimum residual sum of squares. The ratio (regression sum of squares)/(total sum of squares), 'R2', may be used as an estimate of how much of the original variation in y has been explained by the equation. However, this is an optimistic estimate and we prefer the 'adjusted R2' described in the Appendix.
The best subset containing k characteristics may be selected from the many available characteristics using the stepwise method (Nie et al., 1975) . The characteristic giving the largest value of R2 is adopted as xi. Each of the remaining characteristics is then tried, one at a time, as x2 in an equation already containing xi, and the characteristic which gives the largest increment in R2 is retained as x2. This procedure is then repeated for X3 to xk.
Results

EVALUATION OF BIOCHEMICAL INFORMATION IN PRESCRIBING
In 86 of the outpatients, 30 clinical characteristics (including 3 'complex' ones: body surface area (Du Bois and Du Bois, 1916) , estimated lean body mass (Behnke, 1969) , and a cardiac failure score (Dobbs etal., 1976a) ), and 20 biochemical characteristics (including measured and predicted (SiersbaekNielsen et al., 1971 ) creatinine clearance and albumin/globulin ratio) were recorded. Since clinical information is more readily available than biochemical, we compared our ability to predict dose requirement using only clinical information with that using information from both sources (Table 1) . Certain biochemical characteristics, added singly to an equation containing clinical data, improved the prediction, the best of these being the reciprocal of the serum creatinine concentration. The inclusion of further biochemical information was then of little advantage. was still significantly greater than that estimated for the use of our equation (Table 3) .
PRACTICAL APPLICATION
So far it has been assumed that any dose of digoxin can be dispensed. Restricting the predicted doses to practical sizes caused only a slight reduction in the number of patients expected to have mean serum concentrations within the therapeutic range (Table 4) . Calculation of dose requirements using the final equation would require logarithm tables, or preferably a calculator. We, therefore, devised a simplified method (Table 5 ): a score is allocated to each patient according to the 8 characteristics (step 1); the sum of the 8 scores is then entered into a table and the recommended dose read off (step 2). The use of scores caused only a small increase in the error in prediction (Table 4) .
Discussion
The published morbidity associated with digoxin treatment is alarming (Shapiro et al., 1969; Beller et al., 1971) . This causes some doctors to use digoxin only for the control of 'rapid' atrial fibrillation. Others ascribe such signs and symptoms to A score for prescribing digoxin P. W. Nicholson, Sylvia M. Dobbs, A. P. J. McGill, Elaine M. Rodgers, and E. Slater the underlying disease or regard benefit as inseparable from toxicity. When it is conceded that a patient may be receiving an inappropriate dose, the doctor is still unlikely to use prescribing aids: even if he thought them applicable to his patient, he is likely to be deterred by their complexity. The prescribing aid described was based on a group of patients with widely varying characteristics, who were receiving digoxin tablets conforming with the current dissolution standards. Our ability to predict dose requirements was significantly greater using this method than by using alternatives (Jelliffe and Brooker, 1974; Dobbs et al., 1976a) . The risk of achieving mean steady state serum concentrations above the therapeutic range is small using our method, but concentrations below this range are to be expected in one-fifth of cases. (Where a digoxin assay service is available, a single appropriately timed (Dobbs et al., 1976c) blood sample taken during the follow-up period would detect those requiring an alteration in dose.) It is also comparatively simple to use. The need for detailed information about the patient is avoided with only minimal loss of accuracy. In many patients, several of the characteristics will carry a score of zero and so little arithmetic will be required to obtain the total score.
Since, in health, digoxin is excreted mainly by the kidneys, it is not surprising that the characteristics used in the nomogram of Siersbaek-Nielsen et al. (1971) for the prediction of creatinine clearance (serum creatinine concentration, weight, sex, and age) were among the 8 characteristics in our final equation. However, since creatinine production depends on muscle mass rather than total body weight, overprediction of creatinine clearance by the nomogram of Siersbaek-Nielsen et al. is to be expected in patients who are chronically house-or chair bound and in the grossly obese. This might account for the predictive value of the 'mobility' characteristic in our final equation and the finding that no increase in digoxin dose was necessary for body weights exceeding 75 kg. An equation containing measured creatinine clearance or blood urea concentration (Halkin et al., 1975) instead of serum creatinine concentration gave a poorer prediction of dose requirement, probably as a result of incomplete urine collection and variation in protein intake, respectively.
The 'diuretic treatment' and 'heart rhythm' characteristics made significant contributions to the prediction of dose. These findings are in line with previous work. Dobbs et al. (1977a) found that digoxin dose requirement was inversely related to the severity of heart failure, when allowance had been made for differences in serum creatinine concentration, weight, sex, and age. This was partially explained by overprediction of creatinine clearance in these patients, but an increase in tubular reabsorption (Halkin et al., 1975) and/or a reduction in biliary excretion of digoxin may also occur. Beller et al. (1971) found a greater prevalence of atrial fibrillation among patients with digoxin toxicity than those without.
There are several reasons why the out/inpatient characteristic contributed to the predictive value of the final equation. Some inpatients had more pronounced muscle wasting than the outpatients while others had more severe heart failure. Dietary differences may also be important. Fat intake has been shown to bear an inverse relation to dose requirement (Turner et al., 1977) : ill inpatients will tend to consume less fat than outpatients. Every effort to achieve maximal compliance was made in our patients. In the 86 outpatients receiving calendar packs, neither counting the tablets nor the history provided evidence of non-compliance. Moreover the equation derived in these outpatients gave accurate predictions in those not receiving specially packed tablets. This suggests that both groups were equally compliant: the knowledge that the serum digoxin concentration was being monitored may have been the overriding incentive. Where such efforts are not made compliance will be more variable and our prescribing method may apparently underpredict dose requirement.
The prescribing aid, containing these 8 characteristics, gives dosages suitable for patients with normal atrioventricular conduction. Those with impaired conduction, requiring digoxin for the treatment of heart failure, should not be given more than three-quarters of the predicted dose in order to avoid bradycardia (Dobbs et al., 1977b The use of adjusted R2 has the advantage (Huang, 1970) of making allowance for the number (k) of independent variables in the equation. For a sample of n patients it is given by 1 -(1 -R2) (n -1)/
(n -k -1).
STATISTICAL ADEQUACY OF FINAL EQUATION
The validity of the F-tests and of the estimated predictive value of the final equation in a future patient depends on the residual error being normally distributed, and therefore of constant variance, and the equation having no systematic lack of fit. These assumptions were tested as follows.
Residual error was plotted against the predicted log dose requirement for each of our 129 patients (Fig. 1) . This gave no indication that the model was inadequate (Draper and Smith, 1966; Daniel and Wood, 1971) . (A previous trial using dose requirement as the dependent variable in the multiple linear regression analysis had resulted in residual errors which increased with increase in size of the predicted dose, i.e. errors ofnon-constant variance.)
Examination of the plots of residual error against each of the independent variables did not reveal any evidence of lack of fit (Draper and Smith, 1966; Daniel and Wood, 1971 ) between the final equation and the data. The cumulative distribution of the residual errors was plotted (Fig. 2) . By comparison with the cumulative distribution of a similar number of random normal deviates (Daniel and Wood, 1971 ) the figure showed no evidence of lack of normality. The residual variance of the final equation was 1-36 x 10-2. However, if the equation were to be used in a future patient a slightly larger variance would be expected. The increment stems from uncertainty in the equation coefficients resulting from the finite size of our patient sample. Its magnitude would depend on the values of the independent variables in the future patient. When estimated from the variance-covariance matrix of the equation coefficients (Draper and Smith, 1966) , using the combinations of values for independent variables met in our patients, it had a mean of 0-09 x 10-2 and a maximum of 0-25 x 10-2. Taking the mean value, this gave a total estimated residual variance in a future patient of 1-45 x 10-2, i.e. (1 36 + 0-09) x 10-2, with the 95 per cent confidence limits (X2 distribution, degrees of freedom = 120, i.e. n -k -1) shown in Table 3 .
Restricting the doses prescribed by the final equation to practical sizes would cause an additional increase in the residual variance. The doses recommended in Table 5 , step 2, were chosen to correspond to approximately constant increments in log dose, the dose assigned to a patient being that whose log was nearest to the log dose requirement predicted by the equation. This restriction resulted in an increase in the residual variance of the final equation of 0-22 x 10-2 in our patients, and, therefore, an expected residual variance of 1V67 x 10-2, i.e. (1-45 + 0 22) x 10-2, in a future patient. Similarly use of the simplified method of prescribing (Table 5 , steps 1 and 2) resulted in an increase in residual variance of 0-25 x 10-2 in our patients; and, therefore, an expected residual variance of 1-70 x 10-2, i.e. (1A45 + 0-25) x 10-2, in a future patient.
Using the above estimates of residual variance, the probability of a patient achieving a mean steady state digoxin concentration within the therapeutic range when his maintenance dose was selected according to the criteria in Table 4 could be calculated. (A normal distribution was used for this purpose since it is almost identical to the t-distribution with 120 degrees of freedom.)
